Project Grant R01CA299196
Award Date 5/12/26
Completion Date 4/30/31
Dollars Obligated $368K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- Federal Project Grant Summary Mayo Clinic received a $100,228 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2026, with completion targeted for May 5, 2029. This grant supports biomedical research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. The award funds research activities at Mayo Clinic's Rochester, Minnesota facility focused on...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., a Project Grant of $734,942 under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This project addresses cardiovascular disease (CVD) risk in breast cancer survivors by generating novel DNA methylation biomarker data from the Pathways Study, a prospective cohort of 4,504 women diagnosed with...
- Federal Grant Award Summary Mayo Clinic received a $484,803 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 18, 2025, with completion scheduled for July 31, 2030. This research initiative focuses on elucidating glioma risk and improving patient outcomes by integrating germline and somatic genetics analysis. The project addresses critical gaps in understanding the functional relevance of 30 known germline...
- Award Summary Mayo Clinic received a $722,914 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective June 1, 2026, with a completion date of May 31, 2031. This award supports research to develop and validate radiomic phenotypes—quantitative imaging features extracted from three-dimensional digital breast tomosynthesis (DBT) screening examinations—for improved prediction of invasive and advanced breast cancer risk. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. a Project Grant totaling $683,075 under the Cancer Cause and Prevention Research program (CFDA 93.393) on March 24, 2026. This five-year research project, scheduled for completion on February 28, 2031, investigates the mitotic function of 53BP1 and its negative regulator TIRR (TIRR/53BP1 Complex Regulates Mitotic Fidelity and Immune-Mediated Radiation Response). The research examines how...
- GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
- Federal Project Grant Award Summary Mayo Clinic received a $161,400 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for the period August 1, 2025 through July 31, 2027. The award supports research to develop and validate innovative ferroptosis-based therapeutic approaches targeting cholangiocarcinoma (CCA), a highly lethal malignancy of the liver and biliary tract with a five-year survival rate below 10%. The...
- Federal Grant Award Summary Mayo Clinic received a $667,710 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on March 20, 2026, with a completion date of February 28, 2031. The grant supports a randomized Phase 2 clinical trial investigating blood-based biomarkers to optimize treatment strategies for patients with oligometastatic castration-sensitive prostate cancer (OMCSPC). The research evaluates prostate cancer-derived...
- Federal Grant Award Summary The National Cancer Institute awarded a $403,686 Project Grant to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (effective April 7, 2026 through March 31, 2028) under the Cancer Cause and Prevention Research program (CFDA 93.393). The research initiative investigates the role of Cyclin Dependent Kinase 10 (CDK10) in driving aggressiveness and disparities in triple negative breast cancer (TNBC). The project delivers research services...